Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00593229
  4. Details
NCT00593229 Clinical Trial

International Registry and Biorepository for TMA(Thrombotic Microangiopathy)

Thrombotic Thrombocytopenic Purpura Clinical Trial

Official title:
An Observational Study of All Forms of Thrombotic Microangiopathy in Pediatric Patients

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT00593229
Other study ID # DK71221
Secondary ID DK R21-71221
Status Terminated
Phase N/A
First received January 2, 2008
Last updated June 18, 2013
Start date January 2007

Study information
Verified date June 2013
Source Northwell Health
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentUnited States: Institutional Review Board
Study type Observational

Clinical Trial Summary

This registry will collect clinical data and store biosamples (seru, plasma, urine, and DNA) annually from pediatric patients with thrombotic mcroangiopathy

Description:

Children age, 6 months - 18 years, are eligible if they have one of the following categories of thrombotic microangiopathy (TMA):(1) severe D+HUS; (2) non-familial atypical HUS; (3) familial atypical HUS; or (4) TTP

Patients are seen intially and annually thereafter

Biosamples are collected for storage annually.

Recruitment information / eligibility
Status Terminated
Enrollment 6
Est. completion date
Est. primary completion date October 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 6 Months to 18 Years
Eligibility Inclusion Criteria:

- Severe HUS, familial or non-familial atypical HUS, TTP

Exclusion Criteria:

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
United States Schneider Chldren's Hospital New Hyde Park New York

Sponsors (9)
Lead Sponsor Collaborator
Northwell Health Children's Hospital of Philadelphia, Icahn School of Medicine at Mount Sinai, Mario Negri Institute for Pharmacological Research, Montreal Children's Hospital of the MUHC, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Stollery Children's Hospital, University of Utah, University of Virginia

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Determine epidemiology and outcomes of the various forms of TMA Ongoing No
Primary Determine genetic causes of TMA Ongoing No
Secondary Initiate clinical trials in TMA In the future Yes
See also
  Status Clinical Trial Phase
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Recruiting NCT05785468 - A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)
Completed NCT04074187 - A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Phase 2/Phase 3
Terminated NCT00953771 - Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) Phase 2
Recruiting NCT01257269 - Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Not yet recruiting NCT05568147 - Aspirin for Prophylaxis of TTP Phase 2/Phase 3
Recruiting NCT05468320 - Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura Phase 3
Completed NCT00713193 - Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) Phase 3
Completed NCT00426686 - ADAMTS13 in Thrombotic Thrombocytopenic Purpura N/A
Withdrawn NCT00251277 - Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura Phase 1/Phase 2
Recruiting NCT04588194 - Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia Phase 2
Active, not recruiting NCT03237819 - Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care Phase 3
Completed NCT00907751 - Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura Phase 2
Completed NCT03369314 - Observational Study of the Use of octaplasLG®.
Terminated NCT01938404 - Octaplas Adult TTP Trial
Recruiting NCT04981028 - The ConNeCT Study: Neurological Complications of TTP
Completed NCT02134171 - Early Predictive Factors of Cardiac and Cerebral Involvement in TMA N/A
Recruiting NCT05389007 - .German TTP-Registry (Thrombotic Thrombocytopenic Purpura)
Withdrawn NCT02626663 - The Role of Microparticles as a Biomarker
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions